Ecteinascidin 743 (ET-743; yondelis™), aplidin, and kahalalide F

Anticancer Agents from Natural Products

Volumn , Issue , 2005, Pages 215-240

  Henríquez, Rubén ^a   Faircloth, Glynn T ^b   Cuevas, Carmen ^a  

^a PHARMAMAR S A   (Spain)

^b PharmaMar USA Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL TRIAL; DEEP WATER; MARINE ORGANISMS; MODERN MEDICINE; NATURAL PRODUCTS; NATURAL WORLD; PHARMACEUTICAL INDUSTRY; SEA LIFE;

MARINE BIOLOGY;

EID: 33646028136     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (103)

1. Rinehart, K.L., et al., Ecteinascidins 729, 743, 745, 759A, 759B, and 770: potent antitumor agents from the Caribbean tunicate Ecteinascidia turbinata [Erratum to document cited in CA113(9):75189d], J. Org. Chem., 55, 4512–4515, 1990.
2. He, H., Faulkner, D.J., Renieramycins E and F from the sponge Reniera sp.: reassignment of the stereochemistry of the renieramycins, J. Org. Chem., 54, 5822–5824, 1989.
3. Erba, E., et al., Mode of action of Ecteinascidin 743, a natural marine compound with antitumor activity, Ann. Oncol., 9, 535, 1998.
4. Erba, E., et al., Ecteinascidin 743, a natural marine compound with a unique mechanism of action, Eur. J. Cancer, 37, 97–105, 2001.
5. Moore, B.M., et al., Mechanism for the catalytic activation of ecteinascidin 743 and its subsequent alkylation of guanine N2, J. Am. Chem. Soc., 120, 2490–2491, 1998.
6. Seaman, F.C., Hurley, L.H., Molecular basis for the DNA sequence selectivity of Ecteinascidin 736 and 743: evidence for the dominant role of direct readout via hydrogen bonding, J. Am. Chem. Soc., 120, 13028–13041, 1998.
7. Hurley, L.H., DNA and its associated processes as targets for cancer therapy, Nat. Rev. Cancer, 2, 188–200, 2002.
8. Zewail-Foote, M., Hurley, L.H., Differential rates of reversibility of Ecteinascidin 743-DNA covalent adducts from different sequences lead to migration to favoured bonding sites, J. Am. Chem. Soc., 123, 6485–6495, 2001.
9. Sheng, K., et al., Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation, Proc. N.Y. Acad. Sci., 97, 6775–6779, 2000.
10. Minuzzo, M., et al., Interference of transcriptional activation by the antineoplastic drug Ecteinascidin 743, Proc. N.Y. Acad. Sci., 97, 6780–6784, 2000.
11. Jin, S., Hu, Z., Scotto, K., The antitumor agent Ecteinascidin 743 inhibits transcriptional activation of the MDR1 gene by multiple inducers, Clin. Cancer Res., 5, 302, 1999.
12. Mantovani, R., et al., Effect on ET-743 on the interaction between transcription factors and DNA, Ann. Oncol., 9, 534, 1998.
13. Synold, T.W., Dussault, I., Forman, B.M., The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux, Nat. Med., 7, 584–590, 2001
14. Takebayashi, Y., et al., Antiproliferative activity of ecteinascidin 743 is dependent upon transcriptioncoupled nucleotide-excision repair, Nat. Med., 7, 961–966, 2001.
15. Zewail-Foote, M., et al., The inefficiency of incisions of Ecteinascidin 743-DNA adducts by the UvrABC nuclease and the unique structural feature of the DNA adducts can be used to explain the repair-dependent toxicity of this antitumor agent. Chem. Biol., 8, 1033–1049, 2001.
16. Bonfanti, M., et al., Effect of Ecteinascidin 743 on the interaction between DNA binding proteins and DNA, Anticancer Drug Des., 14, 179–186, 1999.
17. Friedman, D., et al., Ecteinascidin 743 inhibits activated by not constitutive transcription. Cancer Res., 62, 3377–3381, 2002.
18. Izbicka, E., et al., Incomplete cross-resistance between ET-743 and standard chemotherapeutic agents against primary tumors in human tumor cloning assay, Ann. Oncol., 9, 130, 1998.
19. Valoti, G., et al., Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts, Clin. Cancer Res., 4, 1977–1983, 1998.
20. Hendriks, H.R., et al., High antitumor activity of ET-743 against human tumor xenografts from melanoma, non-small cell lung and ovarian cancer, Ann. Oncol., 10, 1233–1240, 1999.
21. Riccardi, R., et al., Effective combinations of ET-743 and doxorubicin for tumor growth inhibitions against murine and human sarcomas in athymic mice, Proc. Am. Assoc. Cancer Res., 42, 1132, 2001.
22. D’Incalci, M., et al., The combination of Yondelis and cisplatin is synergistic against human tumor xenografts, Eur. J. Cancer, 39, 1920–1926, 2003.
23. Li, W.W., et al., Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin 743 as a potent cytotoxic agent, Clin. Cancer Res., 7, 2908–2911, 2001.
24. Takahashi, N., et al., Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 with doxorubicin or paclitaxel in soft tissue sarcoma cells, Clin. Cancer Res., 7, 3251–3257, 2001.
25. Faircloth, G.T., In vivo study using tumor containing hollow fibers in the nude mouse, PharmaMar USA report no. 02E01HF, January 15, 2001.
26. Hornicek, F., Weissbach, L., Invasiveness of chondrosarcoma cells in vitro is altered by ET743, Proc. Am. Assoc. Cancer Res., 43, 539, 2002.
27. Faircloth, G.T., Grant, W., Hornicek, F., In vivo combinations of chemotherapeutic agents with ET743 against solid tumors, Clin. Cancer Res., 7, 387, 2001.
28. Faircloth, G.T., et al., Dexamethasone potentiates the activity of Ecteinascidin 743 in preclinical melanoma and osteosarcoma models, Proc. Am. Assoc. Cancer Res., 43, 73, #379, 2002.
29. Morioka, H., et al., Antiangiogenesis treatment combined with chemotherapy produces chondrosarcoma necrosis, Clin. Cancer Res., 9, 1211–1217, 2003.
30. Morioka, H., et al., Antiangiogenesis treatment combined with chemotherapy produces chondrosarcoma necrosis, Clin. Cancer Res., 8, 1211–1217, 2003.
31. Faircloth, G.T., Grant, W., Jimeno, J., Enhancing the preclinical in vivo antitumor activity of Ecteinascidin 743, a marine natural product currently in phase II clinical trials, Clin. Cancer Res., 5, 306, 1999.
32. Ghielmini, M., et al., In vitro schedule dependancy of myelotoxicity and cytotoxicity of Ecteinascidin 743, Ann. Oncol., 9, 989–993, 1998.
33. Albella, B., et al., In vitro toxicity of ET743 and Apldine, two marine-derived antineoplastics, on human bone marrow haematopoietic progenitors: comparison with the clinical results, Eur. J. Cancer, 38, 1395–1404, 2002.
34. Corey, E.J., Gin, D.Y., Kania, R.S., Enantioselective total synthesis of Ecteinascidin 743, J. Am. Chem. Soc., 118, 9202, 1996.
35. Endo, A., et al., Total synthesis of Ecteinascidin 743, J. Am. Chem. Soc., 124, 6552, 2002.
36. Cuevas, C., et al., Synthesis of Ecteinascidin ET-743 and Phthalascidin Pt-650 from Cyanosafracin B, Org. Lett., 2, 2545, 2000.
37. Menchaca, R., et al., Synthesis of natural Ecteinascidins (ET-729, ET-745, ET-759B, ET-736, ET-637, ET-594) from Cyanosafracin B. J. Org. Chem., 68, 8859, 2003.
38. Lopez-Martin, A.J., et al., An exploratory analysis of tumor growth rate (TGR) variations induced by trabectedin (ecteinascidin-743, ET-743) in patients (pts) with pretreated advanced soft tissue sarcoma (PASTS), Proc. Am. Soc. Clin. Oncol., 22, 819, abst. 3293, 2003.
39. Van Glabbeke, M., et al., On behalf of the EORTC Soft Tissue and Bone Sarcoma Group. Progressionfree rate as the principal end-point for phase II trials in soft-tissue sarcomas, Eur. J. Cancer, 38, 543–549, 2002.
40. Colombo, N., et al., Phase II and pharmacokinetics study of 3-hr infusion ET-743 in ovarian cancer patients failing platinum-taxanes, Proc. Am. Soc. Clin. Oncol., 21, 221a, abst. 880, 2002.
41. Grasselli, G., et al., Phase I and pharmacokinetic (PK) study of ecteinascidin-743 (ET, Trabectedin) and cisplatin (P) combination in pre-treated patients (pts) with selected advanced solid tumors, Proc. Am. Soc. Clin. Oncol., 22, 135, abst. 542, 2003.
42. Vermier, M., et al., An Interspecies Comparison of the Metabolism of the Anticancer Agent YondelisTM (Trabectedin, ET-743). Cytochrome P450, Biochemistry, Biophysics and Drug Metabolism. 13th International Conference on Cytochromes P450, Prague, Czech Republic, June 29–July 3, 2003.
43. Rinehart, K.L., Lithgow-Berelloni, A.M., Novel Antiviral and Cytotoxic Agent, PCT Int. Pat. Appl. WO 91.04985, Apr. 18, 1991; GB Appl. 89/22,026, Sept. 29, 1989; Chem. Abstr., 1991, 115, 248086q.
44. Rinehart, K.L., et al., Structures of the didemnins, antiviral and cytotoxic depsipeptides from a caribbean tunicate, J. Am. Chem. Soc., 103, 1857–1859, 1981.
45. Rinehart, K.L., et al., Didemnins and tunichlorin: novel natural products from the marine tunicate Trididemnum solidum, J. Nat. Prod., 51, 1–21, 1988.
46. Urdiales, J.L., et al., Antiproliferative effect of dehydrodidemnin B (DDB), a depsipeptide isolated from Mediterranean tunicates, Cancer Lett., 102, 31–37, 1996.
47. Faircloth, G.T., et al., Dehydrodidemnin B, a new marine derived antitumor agent with activity against experimental tumor models, Ann. Oncol., 7, 34, 1996.
48. Sakai, R., et al., Structure activity relationships of didemnins, J. Med. Chem., 39, 2819–2834, 1996.
49. Erba, E., et al., Mechanism of antileukemic activity of Aplidin, Proc. Amer. Assoc. Cancer Res., 40, 3, 1999.
50. Crews, C.M., et al., GTP-dependent binding of the antiproliferative agent didemnin to elongation factor 1-alpha, J. Biol. Chem., 269, 15411–15414, 1994.
51. Crews, C.M., Lane, W.S., Schreiber, S.L., Didemnin binds to the palmitoyl protein thioesterase responsible for infantile neuronal ceroid lipofuscinosis, Proc. N.Y. Acad. Sci., 93, 4316–4319, 1996.
52. Erba, E., et al., Is Aplidin acting as an ornithine decarboxylase (ODC) inhibitor? AACR-EORTC-NCI Conference, 312, 1999.
53. Izbicka, E., et al., Evaluation of molecular targets for Aplidin, a novel anticancer agent, 11th NCIEORTC-AACR Symposium on New Drugs in Cancer Therapy, 213, 2000.
54. Duranton, B., et al., Concomitant changes in polyamine pools and DNA methylation during growth inhibition of human colonic cancer cells, Exp. Cell Res., 243, 319–325, 1998.
55. Erba, E., et al., Mechanism of antileukemic activity of Aplidin, Proc. Amer. Assoc. Cancer Res., 40, 3, 1999.
56. Broggini, M., et al., Changes in gene expression in tumor cells exposed to the two marine compounds ET-743 and Aplidin by using cDNA microarrays, 10th NCI-EORTC-AACR Symposium on New Drugs in Cancer Therapy, 310, 1998.
57. Broggini, M., et al., Aplidin-induced apoptosis in Molt-4 cells is mediated by its ability to block VEGF secretion, 12th NCI-EORTC-AACR Symposium on New Drugs in Cancer Therapy, 384, 2002.
58. Erba, E., et al., Effect of Aplidin in acute lymphoblastic leukaemia cells, Br. J. Cancer, 89, 763–773, 2003.
59. Bresters, D., et al., In vitro cytotoxicity of Aplidin and crossresistance with other cytotoxic drugs in childhood leukemias and normal bone marrow and blood samples: a rational basis for clinical development, Leukemia, 17, 1338–1343, 2003.
60. Mitsiades, C.S., et al., Preclinical studies of the clinical development of Aplidin® for the treatment of multiple myeloma, American Society of Hematology, 45th Ann. Meeting and Exposition, abst. 250, 2003.
61. Gajate, C., An, F., Mollinedo, F., Rapid and selective apoptosis in human leukemia cells induced by Aplidin through a Fas/CD95-and mitochondrial-mediated mechanism, Clin. Cancer Res., 9, 1535–1545, 2003.
62. Cuadrado, A., et al., Aplidin™ induces apoptosis in human cancer cells via glutathione depletion and sustained activation of the epidermal growth factor receptor, Src, JNK, and p38 MAPK, J. Biol. Chem., 278, 241–250, 2003.
63. Garcia-Fernandez, L.F., et al., Aplidin™ induce the mitochondrial apoptotic pathway via oxidative stress-mediated JNK and p38 and protein kinase C, Oncogene, 21, 7533–7544, 2002.
64. Lobo, C., et al., Effect of Dehydrodidemnin B on human colon carcinoma cell lines, Anticancer Research, 17, 333–336, 1997.
65. Faircloth, G.T., et al., Schedule-dependency of Aplidin, a marine depsipeptide with antitumor activity, 10th NCI-EORTC-AACR Symposium on New Drugs in Cancer Therapy, 394, 1998.
66. Mastbergen, S.C., et al., Cytotoxicity and neurocytotoxicity of Aplidin, a new marine anticancer agent evaluated using in vitro assays, 10th NCI-EORTC-AACR Symposium on New Drugs in Cancer Therapy, 131, 1998.
67. Faircloth, G.T., et al., Preclinical characterization of Aplidin, a new marine anticancer depsipeptide, Proc. Am. Assoc. Cancer Res., 38, 692, 1997.
68. Depenbrock, H., et al., In vitro characterization of Aplidin, a new marine derived anticancer compound, on freshly explanted clonogenic human tumor cells and haematopoietic precursor cells, Br. J. Cancer, 78, 739–744, 1998.
69. D’Incalci, M., et al., New drugs of marine origin, Ann. Oncol., 7, 19, 1996.
70. Faircloth, G.T., et al., Preclinical development of Aplidin, a novel marine-derived agent with potent antitumor activity, 10th NCI-EORTC-AACR Symposium on New Drugs in Cancer Therapy, 129, 1998.
71. Faircloth, G.T., et al., Aplidin is a novel, marine derived depsipeptide with in vivo antitumor activity, Proc. Am. Assoc. Cancer Res., 39, 227, 1986.
72. Gomez, S.G., et al., In vitro hematotoxicity of Aplidin on human bone marrow and cord blood progenitor cells, Toxicology In Vitro, 15, 347–350, 2001.
73. Vera, M.D., Joullié, M.M., Natural products as probes of cell biology: 20 years of didemnin research, Med. Res. Rev., 22, 102–145, 2002.
74. Schmidt, U., Kroner, M., Griesser, H., Total synthesis of the didemnins — I. Synthesis of the peptolide ring, Tet. Lett., 29, 3057, 1988.
75. Schmidt, U., Kroner, M., Griesser, H., Total synthesis of the didemnins — II. Synthesis of didemnins A, B, C and prolyldidemnin A, Tet. Lett., 29, 4407, 1988.
76. Schmidt, U., Kroner, M., Griesser, H., Total synthesis of the didemnins — III. Synthesis of proptected (2R, 3S)-allo-isoleucine and (3S, 4R, 5S)-isostatine derivatives-amino acids from hydroxyl acids, Synthesis, 832–835, 1989.
77. Jou, G., et al., Total synthesis of dehydrodidemnin B. Use of uranium and phosphonium salt coupling reagents in peptide synthesis in solution, J. Org. Chem., 62, 354, 1997.
78. Anthoney, A., Paz-Ares, L., Twelves, C., Phase I And Pharmacokinetic (PK) Study of Aplidin (APL) using A 24-hour, weekly schedule, Proc. Am. Soc. Clin. Oncol., abst. 734, 2000.
79. Ciruelos, E.M., et al., Phase I clinical and pharmacokinetic study of the marine compound Aplidin (APL) administered as a 3 hour infusion every 2 weeks, Proc. Am. Soc. Clin. Oncol., abst. 422, 2002.
80. Bowman, A., et al., Phase I clinical and pharmacokinetic (PK) study of the marine compound Aplidin (APL), administered as A 1 hour weekly infusion, Proc. Am. Soc. Clin. Oncol., abst. 476, 2001.
81. Armand, J.P., et al., Phase I and pharmacokinetic study of Aplidin (APL) given as a 24-hour continuous infusion every other week (Q2w) in patients (Pts) with solid tumor (ST) and lymphoma (NHL), Proc. Am. Soc. Clin. Oncol., abst. 477, 2001.
82. Maroun, J.A., et al., Phase I study of Aplidin in a 5 day bolus Q 3 weeks in patients with solid tumors and lymphomas, Proc. Am. Soc. Clin. Oncol., abst. 2082, 2001.
83. Raymond, E., et al., Phase I (PI) trials with aplidin (APL), a new marine derived anticancer compound, Eur. J. Cancer, 37, S32, 2001.
84. Raymond, E., et al., Activity of APL, a new marine compound, against medullary thyroid carcinoma (MTC): phase I trials as screening tools for rare tumors, Ann. Oncol., 13, 22, 2002.
85. Jimeno, J., et al., Progress in the clinical development of new marine-derived anticancer compounds, Anticancer Drugs, 15, 321–329. 2004.
86. Hamann, M.T., Scheuer, P.J., Kahalalide F., A bioactive depsipeptide from the sacoglossan mollusk Elysia rufescens and the green alga Bryopsis sp., J. Am. Chem. Soc., 115, 5825–5826, 1993.
87. López-Macia, A., et al., Synthesis and structural determination of Kahalalide F, J. Am. Chem. Soc., 123, 11398–11401, 2001.
88. Hamann, M.T., et al., Kahalalides, bioactive depsipeptides from the sacoblassan mollusk Elysia rufescens and the green alga Bryopsis sp., J. Org. Chem., 61, 6594–6600, 1996.
89. Green, B.J., et al., Mollusc-algal chloroplast endosymbiosis. Photosynthesis, thylakoid protein maintenance, and chloroplast gene expression continue for many months in the absence of the algal nucleus, Plant Physiol., 124, 331–342, 2000.
90. Bercero, M.A., et al., Chemical defences of the sacoglossan mollusk Elysia rufescens and its host alga Briopsis sp., J. Chem. Ecology, 27, 2287–2299, 2001.
91. Córdoba, S., et al., In vitro chemosensitivity, cell cycle redistribution and apoptosis induction by Kahalalide F, a new marine compound in a panel of human tumoral cells, Eur. J. of Cancer Suppl., 1, S173, 2003.
92. García-Rocha, M., Bonay, P., Avila, J., The antitumoral compound Kahalalide F acts on cell lysosomes. Cancer Lett., 99, 43–50, 1996.
93. Tartakoff A.M., Perturbations of vesicular traffic with the carboxylic ionophore monensin, Cell, 32, 1026–1028, 1983.
94. Wosikowski, K., Schuurhuis, D., Johnson, K., Identification of epidermal growth factor receptor and c-erbB2 pathway inhibitors by correlation with gene expression patterns, J. Nat. Cancer Inst., 89, 1505–1515, 1997.
95. Suarez, J., et al., A new marine-derived compound induces oncosis in human prostate and breast cancer cells, Mol. Cancer Ther., 2, 863–872, 2003.
96. Sewell, J.M., et al., Kahalalide F appears to promote necrotic cell death in hepatoma cell lines, Proc. Am. Assoc. Cancer Res., abst. 1509, 2004.
97. Janmaat, M.L., et al., Kahalalide F induces caspase-independent cytotoxicity that correlates with HER2 and/or HER3 expression levels and is accompanied by down-regulation of AKT signaling, Proc. Am. Assoc. Cancer Res., abst. 5328, 2004.
98. Nuijen, B., et al., Development of a lyophilized, parenteral pharmaceutical formulation of the investigational polypeptide marine anticancer agent Kahalalide F, Drug Dev. Ind. Pharm., 27, 767–780, 2001.
99. Gómez, S.G., et al., In vitro toxicity of three new antitumoral drugs (trabectedin, aplidin and Kahalalide F) on hematopoietic progenitors and stem cells, Exp. Hemat., 31, 1104–1111, 2003.
100. Brown, A.P., et al., Preclinical toxicity of Kahalalide F, a new anticancer agent: single and multiple dosing regimens in the rat, Cancer Chemother. Pharmacol., 50, 333–340, 2002.
101. Schellens, J.H., et al., Phase I and pharmacokinetic study of Kahalalide F in patients with advanced androgen refractory prostate cancer, Proc. Am. Soc. Clin. Oncol., 451, 2002.
102. Circuelos, C., et al., A phase I clinical and pharmacokinetic study with Kahalalide F in patients with advanced solid tumors with a continuous weekly 1-hour iv infusion schedule, Eur. J. Cancer, 38, 33, 2002.
103. Zelek, L., et al., Preliminary results of Phase II study of ecteinascidin 743 (ET-743) with the 24-hour continuous infusion q3 week schedule in pretreated advanced/metastatic breast cancer patients [Abstract], Proc. 11th NCI-EORTC-AACR Symposium, 6, 45085, 2000.